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Malignant T Cells Secrete Galectins and Induce
Epidermal Hyperproliferation and Disorganized
Stratification in a Skin Model of Cutaneous T-Cell
Lymphoma
Christenze Thode1, Anders Woetmann2, Hans H. Wandall3, Michael C. Carlsson3, Klaus Qvortrup4,
Claudia S. Kauczok5, Marion Wobser5, Andreas Printzlau6, Niels Ødum2 and Sally Dabelsteen1
Cutaneous T-cell lymphomas (CTCLs) are the most common primary skin lymphomas, which are characterized by
an accumulation of malignant T cells in the skin. The early lesion resembles both clinically and histologically
benign inflammatory disorders and also presents with hyperproliferative epidermis and T-cell infiltration. Despite
considerable progress in understanding the molecular mechanisms involved in the malignant transformation of
T cells, the causes of the morphological and histopathological features of the disease are largely unknown. We
used an organotypic model of CTCL to show that malignant T cells through the secretion of galectin-1 and -3
stimulate vigorous growth of keratinocytes. In parallel, malignant T cells induce disorganized keratinocyte
stratification, resembling the early hyperproliferative stage of CTCL. We also observed a loss of attachment
between the epithelial and mesenchymal compartments. In addition, hyperproliferation was followed by a
downregulation of differentiation markers, such as keratin 10 and involucrin, and a decrease in barrier formation.
In conclusion, we provide evidence that malignant T cells orchestrate the histopathological epidermal changes
seen in CTCL.
Journal of Investigative Dermatology (2015) 135, 238–246; doi:10.1038/jid.2014.284; published online 14 August 2014
INTRODUCTION
Cutaneous T-cell lymphoma (CTCL) defines a heterogeneous
group of neoplastic disorders characterized by chronic inflam-
mation and primary accumulation of malignant T cells in the
skin (Girardi et al., 2004). The predominant form of CTCL is
mycosis fungoides (MF), which may present as erythematous
patches or thicker plaques resembling the clinical appearance
of psoriasis and chronic eczema (Abel et al., 1993; Agero
et al., 2007). Histological sections reveal either thickening of
the epithelial layer with infiltration of small-to-medium-sized
lymphocytes with cerebriform nuclei in the upper dermis and
epidermis or thin atopic epithelium (Nickoloff and Griffiths,
1990; Fried and Cerroni, 2012). Despite considerable progress
in understanding the molecular mechanisms involved in the
malignant transformation of T cells, the causes of the morpho-
logical and histopathological features of the disease are largely
unknown. Furthermore, clinical data strongly suggest that
defects in the skin barrier have a key role in the suscepti-
bility to skin infections in CTCL patients. Accordingly,
recurrent or chronic bacterial infections are common, and
in advanced disease, the majority of patients pass away
from infection rather than from the malignancy per se
(Krejsgaard et al., 2011; Wollina, 2012; Willerslev-Olsen
et al., 2013).
Apart from forming the outer barrier of the skin, keratino-
cytes are involved in mediating cutaneous immune responses
producing and responding to cytokines in cross talk with
immune cells in the skin (Streilein, 1978; Nickoloff and
Griffiths, 1990; Dobbeling et al., 1998). Some studies also
suggest that cross talk takes place between malignant T cells
and keratinocytes in CTCL (Celerier et al., 1997; Dobbeling
et al., 1998), but the pathological relevance remains to be
established. Interestingly, malignant T cells spontaneously
produce cytokines, growth factors, and galectins, which
have recently been implicated in chronic skin inflammation
and keratinocyte survival and proliferation (Leroy et al., 2001;
Ferenczi et al., 2002; Nielsen et al., 2002; Roberts et al., 2003;
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Yamanaka et al., 2006; Hsu et al., 2009; Larsen et al., 2011;
Cedeno-Laurent et al., 2012). At present, it is not known
which factors are most important for the induction of disease-
associated morphology of the epithelium, and whether the
morphological changes (1) are directly induced by the
malignant T cells per se, (2) are signs of an overall ineffec-
tive anti-lymphoma response, or (3) are secondary events
(epiphenomena) to bacterial colonization of affected skin.
Given the deregulated activation of tumor-associated signaling
pathways and the production of cytokines, galectins, and
inflammatory and angiogenic factors by malignant T cells, it is
conceivable that malignant T cells per se are key factors in
remodeling the skin (Vacca et al., 1997; Mazur et al., 2004;
Krejsgaard et al., 2006; Kopp et al., 2010; Pedersen et al.,
2013).
Previously, simple (two dimensional) monocultures of cells
were predominantly used in CTCL research. By use of
organotypic models (OCTs) (Maas-Szabowski et al., 2003;
Dezutter-Dambuyant et al., 2006; van den Bogaard et al.,
2014), we now provide insights into the interplay between
malignant T cells and keratinocytes and show that malignant
T cells through the secretion of galectin-1 and -3 elicit marked
epidermal changes involving keratinocyte hyperproliferation
and induce dedifferentiation and signs of compromised func-
tion of the skin barrier.
RESULTS
Hyperplastic keratinocyte layer in vivo and in vitro
To address whether malignant T cells induce keratinocyte
hyperproliferation in vivo, we took advantage of a xenograft
mouse model of CTCL (Krejsgaard et al., 2010b). Malignant
human T cells (MyLa2059) were inoculated subcutaneously in
immune-deficient mice and examined histologically after
3 weeks. We have previously seen that increased number of
injected tumor cells resulted in earlier tumor onset, bigger
tumors, and furthermore skin ulcer formation, which corre-
lates with the occurrence of skin atrophy and ulcer formation
in some CTCL lesions (Supplementary Figure 2 online). In the
tumors with no ulcers, it was a striking observation that the
murine epithelium close to the tumors exhibited a marked
thickening of the epithelial layer toB13 cell layers (Figure 1a,
center), whereas uninvolved skin only comprised three layers
of epithelial cells (Figure 1a, left). Figure 1c shows an
illustrative example of thickening of the epithelial layer
(Figure 1c, right, bars) covering an area characterized by
atypical T cells in the basal layers of the epidermis and the
upper dermis (Figure 1c right, asterisks) in a patient with MF.
The induction by malignant T cells of epithelial thickening
in vivo in the mouse model prompted us to hypothesize that
malignant T cells per se are able to stimulate proliferation of
human keratinocytes, leading to the characteristic phenotypic
lesional skin changes seen in many MF patients. To address
this hypothesis, we took advantage of the OCT model to
investigate whether and how malignant T cells modulate
human keratinocyte growth and the formation of epithelium
under controlled conditions. Figure 1b and c displays skin
formation in the OCT model with or without malignant T cells
or their supernatants. As expected, epidermal OCTs generated
with HaCaT cells (normal immortal human keratinocytes)
without malignant T cells showed normal stratification and
differentiation, with an average of four cell layers (Figure 1b,
left). By contrast, when MyLa2059 cells or supernatant from
MyLa2059 cells was added to the OCT, the epithelial stratifi-
cation and polarity was disrupted, with a combination of
epithelial hyperplasia and hyperproliferation with an average
of 15 cell layers (Figure 1b, middle and right). The same
change was seen with another CTCL-derived malignant T-cell
line (MAC2A) (Supplementary Figure S1b online). Keratino-
cyte hyperproliferation caused by malignant T cells was
verified by staining with the proliferation marker Ki-67. Normal
skin and an OCT with HaCaT cells alone showed positive
staining of a few basal cells in the epithelium (Figure 1c, left
and middle). However, when OCTs were cocultured with
MyLa2059 cells, a significant increase in the number of
Ki-67–positive cells throughout the epithelium was observed
(Figure 1c and d, right). To confirm this effect, we quantified
the hyperproliferation of normal human keratinocytes (NHKs)
and HaCaT cells with and without supernatant from
MyLa2059 cells. A 1.5-fold increase in proliferation was noted
for both cell types upon stimulation (Figure 1e, Po0.05)
(n¼ 10). Six different NHK passages were tested and showed
the same effect on proliferative response (data not shown).
Next, we sought to identify the signaling pathway respon-
sible for the hyperproliferative changes associated with the
interaction between epithelial and malignant T cells. For this
purpose, NHK and HaCaT cells were stimulated with super-
natant from MyLa2059 cells 24 hours before western blot
analysis for the expression and activation status (phosphoryla-
tion) of mitogen-activated protein kinases Erk1/2 and signal
transducer and activator of transcription-3 (STAT3), both of
which have been implicated in mitogen- and cytokine-driven
proliferation of keratinocytes in benign inflammatory skin
disorders (Sano et al., 2005). As displayed in Figure 1g,
keratinocytes responded to malignant supernatant with a
profound increased level of activated STAT3 (i.e., tyrosine
phosphorylation on the activating site (Y705)) (Figure 1f, upper
lane, right versus left). In addition, supernatant from malignant
T cells clearly stimulated an enhanced phosphorylation of
Erk1/2 (Figure 1f, third lane, right versus left). Taken together,
these findings show that malignant T cells stimulate the activa-
tion of key signaling pathways (STAT3 and Erk1/2), which are
implicated in keratinocyte hyperproliferation in benign inflam-
matory skin conditions such as psoriasis (Johansen et al., 2005;
Sano et al., 2005).
Next, we sought to identify the molecular mechanisms
responsible for the hyperproliferative changes associated with
the interaction between epithelial and malignant T cells.
Recently, carbohydrate-binding proteins such as galectins
were implicated in chronic inflammatory skin diseases and
skin cancers including squamous cell carcinoma (Liu and
Rabinovich, 2005; Rabinovich and Toscano, 2009). Moreover,
galectin-1 and -3 drive STAT3 and mitogen-activated protein
kinase (including Erk1/2) signaling in other cell types. Because
galectin-1 and galectin-3 are expressed in situ in CTCL skin
lesions (Roberts et al., 2003; Cedeno-Laurent et al., 2012), we
asked whether these galectins were involved in the promotion
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of keratinocyte hyperproliferation. To this end, we used an
ELISA to measure galectin-1 and -3 secretion by malignant
T cells, and, as shown in Supplementary Table S2 online,
malignant T cells spontaneously secreted large amounts of
galectin-1 and galectin-3, as judged from the levels detected
in supernatants from MyLa2059 cell cultures. Other malignant
T-cell lines including MAC2 and HUT78 also expressed high
levels of galectin-1 and -3 (data not shown). These findings
confirm and extend previous findings by Roberts et al., 2003,
who observed intracellular expression of galectin-1 in the
MyLa2059 and HUT78 cell lines. More importantly, the
induction of keratinocyte hyperproliferation by MyLa2059
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Figure 1. Malignant T cells enhance keratinocyte proliferation. (a) Murine skin from the cutaneous T-cell lymphoma (CTCL) xenograft model: normal thin
epidermis, epithelial hypertrophy/hyperplasia adjacent to the CTCL tumor (anti-CD2 staining). Likewise human mycosis fungoides show epithelial hyperplasia.
Asterisks point to atypical T cells, and bars at the hyperplastic epithelium. (b) Hematoxylin and eosin-stained organotypic cultures (OCTs). Coculture with
malignant T cells or their supernatant resulted in epidermal hyperproliferation, disorganization, and loss of epithelial/mesenchymal contact. (c) Normal Ki-67
distribution in human skin and OCT with HaCaT cells. OCTs with HaCaT and malignant T cells revealed numerous positive keratinocytes in all cell layers; scale
bar¼ 40mm. (d) Quantification of Ki-67-positive cells (n¼ 8). (e) Proliferation of NHK and HaCaT cells stimulated with MyLa2059 supernatant for 24 hours.
Stimulation with supernatant enhanced keratinocyte proliferation significantly, with a 1.5-fold increase in fluorescence intensity (10 independent experiments).
Error bar: SEM. (f) Western blot analysis of whole-cell lysate from HaCaT stimulated with MyLa2059 supernatant showed increased phosphorylation of Erk and
STAT3.
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supernatants was profoundly inhibited following depletion of
galectins. Thus, Myla2059 supernatant subjected to a lactosyl–
sepharose column (which depleted galectin-1 and -3) almost
completely lost the hyperproliferative effect on HaCaT cells
(Figure 2). Similar results were obtained following inhibition
of free galectin-1 and -3 with the galectin inhibitor lactose,
which binds and blocks the carbohydrate-binding sites on
these galectins. Reversely, exogenous galectin-1 or -3 in the
same concentration range as secreted by the Myla2059 cells
induced a proliferative response in HaCaT cells, which was
also similar to the response seen in cultures subjected to
Myla2059 supernatant (Figure 2). Importantly, the proliferative
effect was abrogated using lactose (Figure 2), confirming the
efficacy of lactose-mediated blockage of the galectins in
question. In contrast, the carbohydrate-binding deficient
mutant galectin-3 R186S, previously shown to lack certain
galectin-3 biological functions (Salomonsson et al., 2010), had
no effect on HaCaT proliferation, supporting the conclusion
above that the effect of malignant T cells on keratinocyte
proliferation was mediated, at least in part, by the active form
of galectin-3.
Altered expression of differentiation markers
To characterize the disrupted epithelial stratification, we
assessed the OCT of CTCL with differentiation markers. In
normal skin, keratin 10 and involucrin are expressed in the
suprabasal layers of the epithelium and the staining pattern is
continuous (Figure 3a and d); a similar pattern was seen in the
OCT with HaCaT cells alone (Figure 3b and e). However,
when HaCaT cells were cocultured with MyLa2059 cells, the
epithelium almost completely lost expression of keratin 10
and involucrin, as illustrated by a sporadic and weak staining
pattern (Figure 3c and f). Of note, this expression pattern was
associated with disorganization of the outer layers of the
epidermis.
Loss of adhesion markers and barrier formation
To address whether the histological changes influenced the
integrity and barrier function of the epidermis, we investigated
the expression of molecules involved in intercellular adhesion
of the epidermis. Using flow cytometry we observed that
cocultures of NHK and MyLa2059 induced a decreased
keratinocyte expression, or change of localization, of a series
of adhesion molecules including alpha-3-, alpha-6-, and beta-
4 integrin, and desmoglein-1 (Figure 4b). Essentially similar
findings were observed using conventional immunofluores-
cence staining of monolayer cultures of the keratinocyte cell
line HaCaT treated with or without MyLa2059 supernatant for
48 hours (Figure 4a). As expected, untreated cells formed
monolayers with high expression of alpha-3-integrin at the
cell-to-cell contact borders (Figure 4a, upper left), whereas
exposure to MyLa2059 supernatant profoundly changed the
alpha-3-integrin to an intracellular and granular localization
(Figure 4a, upper, right). Likewise, the expression of alpha-6-
and beta-4- integrin staining was decreased following stimula-
tion with MyLa2059 supernatant (Figure 4a, middle right
versus left and bottom right versus left). A proper skin architec-
ture and barrier rely among other things on the desmosomes,
which strengthen cell-to-cell adhesion connecting the cell
surface on opposing cells to the filament cytoskeleton.
Because flow-cytometric analysis showed a decreased expres-
sion of desmoglein-1 in keratinocytes upon coculture with
MyLa2059 cells, we used transmission electron microscopy to
examine changes in the frequency and structure of desmo-
somes in treated and untreated OCTs. As expected, high
frequencies of classical desmosome structures were observed
in OCTs of HaCaT cells (Figure 4c, left, red arrow). Upon
treatment with MyLa2059 supernatant (Figure 4c, middle row)
and MyLa2059 cells (Figure 4c, right), the distance seemed to
increase between cell membranes in the desmosomes,
although almost equal numbers of desmosomes were present
(Figure 4c, red arrows). To functionally assess whether the
structural changes were paralleled by functional changes in
the desmosome function, we performed a fragmentation assay
on monolayer HaCaT cells treated with MyLa2059 super-
natant or cells, measuring the adhesive resistance of cell
cultures exposed to mechanical stress. Figure 4d shows the
fragmentation response in HaCaT cultures quantitated, and, as
indicated in the graph, exposure to MyLa2059 supernatant
profoundly decreased the resistance of HaCaT cultures to
mechanical stress as evidenced by an increased fragment
score. To further address the functional consequence of the
structural changes in the desmosomes, we examined the effect
of malignant T cells on the barrier function in OCTs of HaCaT
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Figure 2. Malignant T cells and recombinant galectin-1 and galectin-3 that
enhance keratinocyte proliferation. Proliferation of HaCaT cells treated with
indicated stimuli for 24 hours. Fluorescence intensity of cells just stimulated
with DMEM media indicated by the dotted line. Stimulation with Myla2059
supernatant or 50 nM galectin-3 enhanced the proliferation of keratinocytes
significantly (****Po0.0001), as seen by a fourfold increase in fluorescence
intensity, whereas 50 nM galectin-1 induced less proliferation, 2.5-fold,
however, still significant (*P¼0.0439). Eliminating galectins either by running
supernatant through a lactosyl–sepharose column or by the addition of 50 mM
lactose inhibiting galectin binding reduced proliferation almost back to
baseline. Galectin-3 R186S (50 nM), which has lost its ability to bind
carbohydrates (LacNAc), is used as a negative control (eight independent
experiments). Error bar: SEM. The differences in fluorescence levels between
different stimulations were calculated using the Student’s t-test. NS, not
significant.
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cells. To this end, the cultures were stained on the surface
with multiple stain solution for 30 minutes before fixation
and analysis of the penetration of stain into the keratinocyte
layers in the OCT. As shown in Figure 4e right, only the most
superficial top two cell layers were stained in the control
OCTs, whereas cell layers were stained to a depth of
approximately one half the total depth of the epithelium
following coculture with MyLa2059 cells, indicating that the
barrier function was profoundly decreased and confirming the
data above on a compromised structure and function of
desmosomes.
DISCUSSION
Epithelial hyperproliferation is a key feature of many skin
diseases, including many of the early stages of CTCL. The OCT
we utilized in the present study portrays several of the key
features of many early human CTCL lesions, including
hyperproliferation of keratinocytes and damaged barrier func-
tion due to marked downregulation of differentiation markers.
These changes mimic the pathological changes seen in the
plaque form of CTCL, and may explain the increased risk of
bacterial infections in patients with CTCL. To our knowledge,
the present study is the first to include malignant T cells in
OCTs to investigate their influence on keratinocyte differentia-
tion and skin architecture. Our OCT demonstrates that
malignant T cells profoundly change the behavior, growth,
and function of keratinocytes. Accordingly, the OCT of CTCL
may be a promising tool to investigate the pathology of the
disease, especially the early stages. A few studies have
included immune cells derived from CD34þ hematopoietic
progenitor cells or peripheral blood mononuclear cells in
OCTs (Jacobs et al., 1998; Dezutter-Dambuyant et al., 2006).
In these studies, the inclusion of normal immune cells did not
change keratinocyte proliferation, differentiation, or barrier
formation, indicating that the changes reported in the present
study are uniquely related to the malignant T cells.
In the present study, we provide evidence that malignant
T cells secrete considerable amounts of galectin-1 and -3.
These data confirm and extend other findings of galectin-1 in
cell lysates of malignant T cells and immunohistochemical
stainings demonstrating expression of galectins in situ in skin
lesions from CTCL patients. Previous studies have implicated
galectins in cross talk between malignant and nonmalignant T
cells affecting T-cell balance in the tumor environment
promoting a skewing towards a Th2 response which could
favor tumor survival (Cedeno-Laurent et al., 2012). In this
respect, the Myla2059 cells have been shown to be resistant to
galectin-1 and -3-induced apoptosis, which explains why
malignant T cells can survive in a self-created hostile environ-
ment (Roberts et al., 2003; Krejsgaard et al., 2010a). Galectins
have a wide range of important biological activities and
function as modulators of proliferation and migration (Song
et al., 2014). In keeping with this, galectin-1 and -3 promote
cell proliferation (Song et al., 2014) and stimulate several
signal pathways including the STAT3, mitogen-activated
protein kinase pathways such as p38 and Erk1/2, and the
Akt signaling pathway (Masamune et al., 2006; Sakaguchi
et al., 2006). Of particular interest, galectin-1 and -3 promote
keratinocyte survival and have been implicated in benign
inflammatory skin diseases and skin cancer characterized by
an abnormal keratinocyte proliferation, survival, and differen-
tiation (Rabinovich et al., 2012). Whether specific cytokines
enhance the effect of galectins has to be further investigated.
Our findings that (i) the proliferative effect of malignant T-cell
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Figure 3. Organotypic model of cutaneous T-cell lymphoma (CTCL) demonstrates downregulation of differentiation markers when MyLa2059 cells are added to
the culture. Differentiation-related protein expression was altered in the organotyic model of CTCL. Control organotypic model using HaCaT cells (b, e) showed
expression of differentiation markers keratin 10 and involucrin similar to that of epidermal tissue in vivo (a, d). The epithelium of organotypic models with
MyLa2059 cells (c and f), however, exhibited a weak staining of both proteins and only sporadic expression; scale bar¼50mm.
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media on keratinocytes was compromised following galectin
depletion and (ii) addition of galectin-1 and -3 in the same
concentration range found in the T-cell supernatant by us and
others (Sakaguchi et al., 2006) induced cell proliferation
strongly suggest that these lectins in part could be respon-
sible for the hyperproliferative stage of CTCL.
Patients with CTCL frequently pass away from bacterial
infections and not from their cancer, because of the disrupted
barrier function that develops as the disease progresses
(Dietz et al., 1996). We observed a marked increase in skin
permeability following the exposure to conditioned media
from malignant T cells. A partial explanation could be the
observed downregulation of both involucrin, keratin 10, and
adhesion molecules desmoglein-1, beta-4-, alpha-3-, and
alpha-6- integrin, which might also be reflected in the
increased distance between the individual keratinocytes
visualized by electron microscopy. This increased permeability
might be an explanation for the epidermotropism seen in
CTCL, as the access for the T cells will be easier. In addition to
the results obtained with the human keratinocyte cell line
HaCaT, we also created the model with NHKs forming
a well-defined stratum corneum. Coculture with either
malignant T cells or with conditioned media from malignant
T cells induced massive lesions of the keratinocytes, causing
ulcer-like lesions with complete detachment of the
keratinocytes from the dermal compartment (Supplementary
Figure 1 online). This phenotype, also observed in the
large and established xenograft tumors in the mouse model
and in prolonged culture in the OCT model (data not shown),
may reflect the atopic and ulcerative lesions commonly
seen in progressed CTCL lesions. This profound effect is seen
earlier on NHKs and is probably due to their more fragile
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Figure 4. HaCaT stimulated with MyLa2059 supernatant altered cell adhesion and decreased the barrier function. (a) Immunofluorescent staining of HaCaT cells
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phenotype compared with HaCaT cells, both in relation to
proliferation and to the altered expression of adhesion
proteins.
In conclusion, our study shows that malignant T cells drive
important changes in the epidermis in CTCL, including
hyperproliferation and loss of the epidermal barrier function.
Malignant T cells induce downregulation of key barrier
proteins in keratinocytes and an increased intercellular dis-
tance possibly caused by loosely packed desmosomes. This
leads subsequently to increased epithelial permeability, which
may at least partly explain why CTCL patients often suffer from
an increased risk of recurrent and severe bacterial infections
(Jackow et al., 1997; Macias et al., 2011). Importantly,
galectins secreted by malignant T cells seem to be key
regulators of keratinocyte proliferation and thereby of the
hypertrophy seen in many MFs skin lesions.
MATERIALS AND METHODS
Cell culture
NHK, dermal fibroblasts, and T cells were isolated from healthy skin
obtained during reconstruction surgery at BodyLift Center, Virum.
Written informed consent was obtained, and the study was performed
in accordance with the Declaration of Helsinki Principles. Primary
cells were isolated according to Gangatirkar et al. (2007). The
malignant T-cell lines MyLa2059 and MAC2A originated from
patients with MFs. Immortalized human keratinocytes (HaCaT cells)
were obtained from Charlotte M. Bonefeld, at the Department of
International Health, Immunology & Microbiology.
NHK and HESderKs were cultured in serum-free media (Gibco,
Invitrogen, Taastrup, Denmark) as described (Dabelsteen et al., 2009),
and cell passages 1–6 were used. HaCaT cells and human fibroblasts
were grown in DMEM supplemented with 10% heat-inactivated
fetal calf serum (HyClone, Logan, UT), 100 IU ml 1 penicillin, and
100mg ml 1 streptomycin. Normal T cells were grown in RPMI1640
(Sigma-Aldrich, Brndby, Denmark) supplemented with 20% fetal
calf serum (Hyclone), 100 IU ml 1 penicillin, 100mg ml 1 strepto-
mycin (Life Technologies, Nærum, Denmark), 107 U ml 1 interleu-
kin-2 (Proleukin, Novartis, Copenhagen, Denmark), and DynaBeads
Human T-Activator CD3/CD28 (Life Technologies). MyLa2059 cells
were cultured in RPMI1640 supplemented with 10% fetal calf serum.
Organotypic culture
Organotypic cultures were prepared as previously described
(Dabelsteen et al., 2009). In brief, human skin fibroblasts were
embedded in rat collagen I in culture inserts with 3-mm-pore
polycarbonate filters (BD Biosciences, Brndby, Denmark). Epithelial
cells were seeded on contracted gels in mitogen-supplemented
DMEM/F12 medium (Parenteau et al., 1992). Inserts were sub-
sequently raised to the air–liquid interface. To establish an organo-
typic culture system mimicking CTCL, MyLa2059 cells (104–5 104,
and exchanged every second day) or supernatant from MyLa2059
cells were added to the inserts 24 hours after seeding the epithelial
cells. Controls without malignant T cells were run in parallel.
Organotypic cultures were also performed with de-epidermized
dermis as the dermal equivalent, as described by Ridky et al.
(2010). OCTs were fixed in 10% formalin, paraffin embedded, and
sectioned for immunostaining, or fixed for transmission electron
microscopy as described below.
Proliferation assay
We used the CyQuant Cell Proliferation Assay Kit (Life Technologies)
in accordance with the manufacturer’s protocol. Prior to the assay,
MyLa2059 cells (106 ml 1) were cultured in keratinocyte serum-free
medium to avoid fetal calf serum stimulation, and supernatant was
collected after 48 hours. Keratinocytes were grown in 96-well culture
plates for 24 hours with or without supernatant stimulation. Galectins
were removed from media using a 1-ml lactosyl–sepharose column
essentially as described for galectin purification (Sorme et al., 2004).
Keratinocytes were grown in 96-well culture plates for 24 hours with
or without Myla2059 supernatant (including galectin-depleted
supernatant and 50 mM lactose-treated supernatant) or with galectins
at a concentration of 50 nM with or without 50 mM lactose. At the
indicated time, plates were rinsed in sterile phosphate-buffered saline
and discharged, and cells in the microplates were frozen at  80 1C.
To quantitate the samples, cells were lysed, and total cellular nucleic
acid was measured by fluorescence at 520 nm emission after
excitation at 480 nm.
Immunohistochemistry
Immunohistochemistry was performed with the DAKO Envision
system (antibody data see Supplementary Table 1 online). Counter-
staining with either hematoxylin or Light Green (Gurr; VWR Interna-
tional, West Chester, PA) was carried out. Sections were examined
under a Leica light microscope (Leica Microsystems A/S, Herlev,
Denmark), and all images were recorded at  25 magnification with
a Colorview Soft Imaging System camera (Olympus, Tokyo, Japan).
Immunofluorescence was performed as previously described
(Wandall et al., 2007). Sections were incubated with primary anti-
bodies overnight at 4 1C and for 1 hour with conjugated secondary
antibody and mounted with ProLong Gold Antifade Reagent with
diamidino-2-phenylindole (Life Technologies). Images were recorded
with a Leica fluorescence microscope at  40 magnification using a
Leica camera.
The working dilution of the antibodies was established by titration
on sections of an organotypic culture that was prepared with normal
human cells. The minimum concentration providing a positive
staining in normal epithelium was used.
Transmission electron microscopy
Fixed samples (2% v/v glutaraldehyde in 0.05 M sodium phosphate
buffer (pH 7.2)) were rinsed in 0.15 M sodium cacodylate buffer (pH
7.2) and subsequently postfixed in 1% w/v OsO4 in 0.12 M sodium
cacodylate buffer (pH 7.2) for 2 hours. The samples were dehydrated
and transferred to propylene oxide and embedded in Epon according
to standard procedures. Ultra-thin sections were cut with a Reichert-
Jung Ultracut E microtome (Depew, NY), collected on one-hole
copper grids with Formvar supporting membranes, and stained with
uranyl acetate and lead citrate. Sections were investigated with a
Philips CM 100 TEM (Philips, Eindhoven, The Netherlands), operated
at an accelerating voltage of 80 kV. Images were recorded with an
OSIS Veleta digital slow scan 2 k 2 k CCD camera and the ITEM
(Olympus) software package.
Permeability assay
Prior to fixation, the permeability assay was performed on matured
OCTs on de-epidermized dermis. Multiple Stain Solution (Polysciences,
Warnington, PA) was applied on the epithelium and incubated at
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37 1C for 30 minutes. Excess dye was removed in 70% ethanol, and
gels were fixed for 1 hour in 10% formalin and then overnight in 3%
paraformaldehyde at 4 1C.
Galectin ELISA
Galectin-1 and -3 levels in the T-cell supernatant (106 cells ml 1)
were measured with competitive ELISA as previously described
(Carlsson et al., 2011).
Flow cytometry
NHK and HaCaT cells were grown to 40% confluency with either
MyLa2059 cells or supernatant from these cells for 72 hours. Prior to
flow cytometry the media was changed to Ca2þ -free media (Invitro-
gen) for 2 hours and then harvested using 2.5 mg ml 1 Dispase
(Roche Diagnostics A/S, Hvidovre Denmark) in phosphate-buffered
saline at 37 1C for 25 minutes. Cells were stained with the appropriate
antibodies (see Supplementary Table 1 online).
Data acquisition and flow-cytometric analysis were conducted on a
BD LSRII using FACSDiva software (Becton Dickinson, Franklin
Lakes, NJ).
Production of recombinant galectin
Recombinant human galectin-1 C3S, galectin-1 and galectin-3 were
produced in E. coli BL21 Star and purified by chromatography on
lactosyl–sepharose as previously described (Sorme et al., 2004).
Protein extraction and western blotting
Protein extraction and western blotting were performed as described
previously (Kopp et al., 2010). Total protein concentration of each
lysate was determined with the Bio-Rad protein assay (Bio-Rad,
Hercules, CA).
Mouse xenograft tumor model
In brief, NOD/SCID-B2m / mice were transplanted with human
MyLa2059 cells, the same malignant T-cell line used in the skin model,
which led to rapid tumor formation within 3 weeks. The biopsy
included the CTCL tumor and the surrounding uninvolved skin, and
sections were studied by histological analysis (Krejsgaard et al., 2010b).
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